Systematic Review And Meta-Analysis Of Psoriasis Treatments.

Psoriasis Clinical Trial

Official title:

Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01425138
• Other study ID #: A3921142
• Status: Completed
• Start date: June 2009
• Est. completion date: June 2011

Study information

• Verified date: November 2018
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data.

Description:

This project involved a systematic literature review of published trials of treatments for moderate-to-severe plaque psoriasis. Data was extracted from the publications on various psoriasis endpoints including the Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), and Short-Form 36 (SF-36). A traditional meta-analysis and a mixed treatment comparison was conducted on the extracted data. We included all published randomized controlled trials of treatments for moderate-to-severe psoriasis that met the study inclusion criteria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: June 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Randomized controlled clinical trials of treatments for moderate-to-severe plaque psoriasis.

• Trials had to evaluate at least one of the following: Physician's Global Assessment (PGA), Dermatology Life Quality Index (DLQI) and/or the Short-Form 36 (SF-36).

Exclusion Criteria:

Observational studies

• Trials that did not report the Physician's Global Assessment (PGA),

• Dermatology Life Quality Index (DLQI) or the Short-Form 36 (SF-36).

Related Conditions & MeSH terms

• Psoriasis

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Pfizer	University of Connecticut School of Pharmacy and Hartford Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Physician Global Assessment (PGA)
Primary	Dermatology Life Quality Index (DLQI)
Primary	Short-Form 36 (SF-36)
Secondary	No secondary outcomes		No secondary outcomes

External Links

•   To obtain contact information for a study center near you, click here.